CD4 and COVID-19: These results preliminarily suggest that circulating EM DN (CD4- CD8-) % DN reduces the inhibitory effect of Myristate (14:0) on severe COVID-19 by down-regulating the level of Myristate (14:0) in blood, thereby increasing the risk of severe COVID-19.